Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl
申请人:Università Degli Studi Di Milano - Bicocca
公开号:EP2161271A1
公开(公告)日:2010-03-10
The present invention relates to compounds of formula (I)
wherein R1, R2 and R3 are as defined in the description,
to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumours (IMT) and non-small cell lung cancer (NSCLC).